Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy.
Dogan Erdogan, Hakan Gullu, Mustafa Caliskan...
https://pubmed.ncbi.nlm.nih.gov/17065184Actively Recruiting
Phase 4
Age: 18Years +
All Genders
Healthy Volunteers
ID06864234
Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA: a Randomised, Placebo-controlled, Mechanistic Study
Led by VZW Cardiovascular Research Center Aalst · Updated on 2025-07-14
46
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating whether beta-blockers can improve coronary blood flow and reduce resistance in patients with angina and no obstructive coronary arteries (ANOCA). This trial aims to answer if beta-blockers improve coronary blood flow and lower coronary microvascular resistance. The study compares a beta-blocker to a placebo in patients undergoing diagnostic angiography and found to have ANOCA, focusing on detailed coronary function measurements. Participants will be randomly assigned to receive either intravenous metoprolol, a beta-blocker, or a saline placebo. Before treatment, baseline measurements of coronary blood flow and resistance are taken using continuous intracoronary thermodilution, a precise method involving a pressure/temperature guidewire and infusion catheter. After administration, these measurements are repeated 10 minutes later to assess treatment effects. The procedure takes about 15 minutes and is performed under blinded conditions. During the study, participants undergo diagnostic angiography and detailed heart function tests including pressure and flow measurements at rest and during increased blood flow. Researchers measure parameters such as absolute coronary flow, microvascular resistance, epicardial resistance, coronary flow reserve, and myocardial perfusion. The study monitors changes from baseline to 10 minutes post-intervention to understand the impact of beta-blockers on coronary microvascular function and overall heart circulation.
CONDITIONS
Brief Title
Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Patients undergoing diagnostic coronary angiography for suspected angina pectoris who are found to have ANOCA with FFR >0.80 and no diameter stenosis >50%
- Normal TIMI 3 flow at angiography
- Stable haemodynamics
- Age 18 years or older
You will not qualify if you...
- Clinical signs or symptoms of congestive heart failure
- Severe valvular heart disease requiring surgical or percutaneous intervention
- History of coronary artery bypass grafting
- Tortuous coronary anatomy complicating wire manipulation
- Heart rate less than 60 beats per minute
- Systolic blood pressure less than 100 mmHg
- Unable to give consent
- Left ventricular ejection fraction less than 40%
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) during diagnostic coronary angiography
Treatment
Duration - Approximately 15 minutes
Participants receive a single intravenous dose of either beta-blocker (metoprolol) or placebo, and undergo detailed cardiovascular measurements before and 10 minutes after administration to assess the effect of the intervention on coronary flow and resistance.
1 visit (in-person) including baseline and post-intervention assessments
Trial Site Locations
Total: 1 location
1
OLV Cardiovascular Center Aalst
Aalst, Flanders, Belgium, 9300
Actively Recruiting
Loading map...
Research Team
A
Adriaan Wilgenhof, MD
T
Thabo Mahendiran, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease.
Maurizio Galderisi, Silvana Cicala, Arcangelo D'Errico...
https://pubmed.ncbi.nlm.nih.gov/15480106Beta-adrenergic blockade and myocardial perfusion in coronary artery disease: differential effects in stenotic versus remote myocardial segments.
Pascal Koepfli, Christophe A Wyss, Mehdi Namdar...
https://pubmed.ncbi.nlm.nih.gov/15471825Effect of beta 1 adrenergic receptor blockade on myocardial blood flow and vasodilatory capacity.
M Böttcher, J Czernin, K Sun...
https://pubmed.ncbi.nlm.nih.gov/9074535Does the beta-blocker nebivolol increase coronary flow reserve?
Mario Togni, Francesco Vigorito, Stephan Windecker...
https://pubmed.ncbi.nlm.nih.gov/17235472Do beta-adrenergic blocking agents increase coronary flow reserve?
M Billinger, C Seiler, M Fleisch...
https://pubmed.ncbi.nlm.nih.gov/11738286